Table 1

Demographics and characteristics

Total subjects, N=111Early-glaucoma group, N=86Glaucoma suspect group, N=25P value
Age (years)57.0±12.459.5±8.757.9±13.40.270*
Sex (male/female)41/7035/516/190.128†
IOP (mm Hg)13.0±2.713.0±2.713.1±2.50.851*
CCT (um)536.3±34.2536.6±35.1535.7±31.70.921*
Axial length (mm)24.45±1.5824.52±1.5924.10±1.540.410*
Diabetes mellitus13 (11.7%)11 (12.8%)2 (8.0%)0.729‡
Systemic hypertension28 (25.2%)23 (26.74%)5 (20.0%)0.494†
Macular SMD (m–1)
 Nasal quadrant23.08±4.7323.26±5.2322.46±2.290.102§
 Superior quadrant25.67±41525.90±4.5324.90±2.330.159§
 Temporal quadrant20.93±4.0520.53±4.2222.26±3.140.061*
 Inferior quadrant20.95±5.0020.54±5.0022.37±2.570.016*
 SN sector25.49±5.6125.78±6.1524.50±3.040.107§
 SS sector26.27±4.2726.58±4.4425.19±3.450.154*
 ST sector23.23±4.0823.25±4.3523.13±3.050.001§
 IT sector19.05±4.7918.19±4.8322.07±3.25<0.001*
 II sector20.24±4.9219.42±5.1423.04±2.58<0.001*
 IN sector22.69±5.1722.56±5.5823.12±3.410.538*
Mean deviation (dB)−1.68±1.91−2.21±1.560.12±1.92<0.001*
PSD (dB)4.07±2.814.78±2.811.63±0.32<0.001§
Medications
 Topical BB40 (36.0%)36 (41.9%)4 (16.0%)0.018†
 Topical CAI21 (18.9%)20 (23.3%)1 (4.0%)0.022‡
 Topical AA18 (16.2%)16 (18.6%)2 (8.0%)0.170‡
 Topical PGA59 (53.2%)56 (65.1%)3 (12.0%)<0.001‡
 Systemic GB2 (1.8%)2 (2.3%)0 (0.0%)0.599‡
 Systemic CCB5 (4.5%)5 (5.8%)0 (0.0%)0.272‡
  • *Student t-test

  • †χ² test.

  • ‡Fisher's exact test.

  • §Mann-Whitney test.

  • AA, alpha-agonists; BB, beta-blockers; CAI, carbonic anhydrase inhibitors; CCB, calcium channel blockers; CCT, central corneal thickness; GB, Ginkgo Biloba;GS, glaucoma-suspect; II, inferoinferior; IN, inferonasal; IOP, intraocular pressure; IT, inferotemporal; PGA, prostaglandin analogues; PSD, pattern SD; SMD, superficial microvessel density; SN, superonasal; SS, superosuperior; ST, superotemporal.